Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Retained Earnings: 2019-2024

Historic Retained Earnings for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$754.6 million.

  • Kymera Therapeutics' Retained Earnings fell 43.15% to -$979.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$979.0 million, marking a year-over-year decrease of 43.15%. This contributed to the annual value of -$754.6 million for FY2024, which is 42.18% down from last year.
  • Latest data reveals that Kymera Therapeutics reported Retained Earnings of -$754.6 million as of FY2024, which was down 42.18% from -$530.8 million recorded in FY2023.
  • Over the past 5 years, Kymera Therapeutics' Retained Earnings peaked at -$128.8 million during FY2020, and registered a low of -$754.6 million during FY2024.
  • Its 3-year average for Retained Earnings is -$556.4 million, with a median of -$530.8 million in 2023.
  • Data for Kymera Therapeutics' Retained Earnings shows a maximum YoY tumbled of 77.83% (in 2021) over the last 5 years.
  • Over the past 5 years, Kymera Therapeutics' Retained Earnings (Yearly) stood at -$128.8 million in 2020, then crashed by 77.83% to -$229.0 million in 2021, then tumbled by 67.61% to -$383.8 million in 2022, then slumped by 38.29% to -$530.8 million in 2023, then slumped by 42.18% to -$754.6 million in 2024.